The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

Plozasiran shows promise in reducing cholesterol and triglyceride levels in patients with mixed hyperlipidemia and other harmful conditions, addressing significant cardiovascular risks.

Student pharmacists can work toward a better future for patients, themselves, and the profession.

The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo.

With the FDA approval, avutometinib/defactinib is now the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

New research reveals that B vitamins and choline may slow glaucoma progression, offering hope for innovative treatments beyond traditional methods.

The Ensuring Community Access to Pharmacist Services (ECAPS) Act would enhance Medicare coverage for pharmacist services and ensure seniors can access essential care in underserved areas.

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.

Pharmacists can educate patients on nonpharmacologic strategies that help improve survival outcomes.

The agent demonstrated promising tolerability and manageable safety.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.

Adherence to GLP-1 receptor agonists showed a 59% drop in inpatient hospital costs.

The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients.

Patients with myelofibrosis who stopped ruxolitinib on the first day of conditioning did not show higher rates of acute graft-versus-host disease (GVHD).

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

AI transforms pharmacy practice by streamlining workflows and enhancing patient care, while pharmacists adapt to new roles and challenges in health care.

The time frame concept is an underappreciated through line in most planning efforts.

Intravenous immunoglobulin (IVIG) treatment for dermatologic conditions shows effectiveness but poses risks of kidney decline and thromboembolism, necessitating careful monitoring.

The agent targets B7-H3, a commonly overexpressed protein in diffuse intrinsic pontine glioma (DIPG).

There was no significant increase in severe adverse events associated with statin use.